**Name of Journal: *World Journal of Clinical Pediatrics***

**ESPS Manuscript NO: 21251**

**Manuscript Type: MINIREVIEWS**

**Use of corticosteroids during acute phase of Kawasaki disease**

Yu JJ. Use of corticosteroids for Kawasaki disease

**Jeong Jin Yu**

**Jeong Jin Yu,** Department of Pediatrics Cardiology, College of Medicine, Ulsan University, Ulsan 680-749, South Korea

**Jeong Jin Yu,** Department of Pediatrics, Asan Medical Center, Seoul 138-736, South Korea

**Author contributions:** Yu JJ solely contributed to this manuscript.

**Conflict-of-interest** **statement:** I have no relevant financial relationships to disclose or conflicts of interest to resolve.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Correspondence to:** **Jeong Jin Yu, MD, PhD,** Department of Pediatrics, Asan Medical Center, 88, Olympic-ro 43-gil, Songpa-gu, Seoul 138-736, South Korea. pediatrist@medimail.co.kr

**Telephone:** +82-02-30103924

**Fax:** +82-2-4733725

**Received:** July 2, 2015

**Peer-review started:** July 8, 2015

**First decision:** August 25, 2015

**Revised:** August 28, 2015

**Accepted:** October 16, 2015

**Article in press:**

**Published online:**

**Abstract**

In spite of initial intravenous immunoglobulin (IVIG) treatment, a significant number of patients are unresponsive to it and are at a higher risk for coronary artery lesions. Corticosteroids have been used as a secondary drug or used in combination with IVIG. Three options of using corticosteroids for the treatment of patients during the acute phase of Kawasaki disease, have been considered. The first is their use exclusively for patients unresponsive to IVIG treatment. The second is their use in combination with IVIG as the routine first line therapy for all patients. The last is the use in the combination as the first line therapy for selected patients at a high risk being unresponsive to initial IVIG. However, it is uncertain that the corticosteroids as the second line treatment are better than the additional IVIG in patients unresponsive to initial IVIG. The combination of corticosteroids and IVIG as the routine first line therapy also have not enough evidences. The last option of using corticosteroids - the combination of corticosteroids and IVIG in patients at high risk of unresponsiveness, is a properly reasonable treatment strategy. However, there have been no globally standardized predictive models for the unresponsiveness to initial IVIG treatment. Therefore, future investigations to determine the best predictive model are necessary.

**Key words**: Kawasaki disease; Corticosteroids; Methylprednisolone; Prednisolone; Immunoglobulins; Coronary aneurysm; Fever

**© The Author(s) 2015.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** In spite of initial intravenous immunoglobulin (IVIG) treatment, a significant number of patients are unresponsive to it and are at a higher risk for coronary artery lesions. Corticosteroids have been used as a secondary drug or used in combination with IVIG. There are several options of using corticosteroids for the treatment of patients with Kawasaki disease during the acute phase. A thorough review of the use of corticosteroids in acute phase Kawasaki disease was performed in this paper.

Yu JJ. Use of corticosteroids during acute phase of Kawasaki disease. *World J Clin Pediatr* 2015; In press

**INTRODUCTION**

Kawasaki disease is an acute, self-limited systemic type of vasculitis which occurs predominantly in young children. Kawasaki[1] firstly reported it in 1967, and it is now acknowledged as a common acquired heart disease of children in many developed countries. The etiology of Kawasaki disease is currently unknown. It is a reasonable open hypothesis that Kawasaki disease is caused by an unidentified microorganism that induces striking immune perturbations in genetically susceptible individuals. Although the efforts to find a causative microorganism have failed[2-4], the suspicion of an association between some unidentified microorganism and Kawasaki disease remains[4-7]. Investigations to identify a genetic susceptibility locus in Kawasaki disease also have been performed recently[8-10]. Several institutes had cooperated and reported a result regarding the genetic susceptibility of Kawasaki disease[11]. A recent review[12] further explains the related genetic studies. The standard first line therapies during the acute phase are an intravenous infusion of immunoglobulin (IVIG) and the administration of a high dose of aspirin[13]. Corticosteroids were used as the first line therapy before Kato *et al*[14] suggested the possibility of an aggravation of coronary artery lesions caused by them. Another report[15] to the contrary was quieted because the strong therapeutic efficacy of IVIG was reported in 1984[16]. More than 10 years after the introduction of IVIG, there were reports of the successful therapeutic application of corticosteroids for children with Kawasaki disease unresponsive to initial IVIG treatment in whom neither significant aggravation of coronary artery lesions nor other adverse effects were found after the administration of corticosteroids[17-19]. In addition, a question about the study by Kato *et al*[14], in which an information about randomization methods was not provided, was raised[17-19].

According to the guidelines of American Heart Association (AHA) in 2004, corticosteroids treatment could be recommended for children in whom ≥ 2 infusions of IVIG have been ineffective in alleviating the fever and acute inflammation[13]. However, corticosteroids have been occasionally used more early as the second line therapy for patients unresponsive to initial IVIG treatment, as the routine first line therapy in combination with IVIG, or as the first line therapy in combination with IVIG for selected Kawasaki disease patients at a high risk of unresponsiveness to initial IVIG.

**THE EXCLUSIVE USE OF CORTICOSTEROIDS IN PATIENTS UNRESPONSIVE TO IVIG TREATMENT**

The best second line therapeutic methods for patients unresponsive to initial IVIG treatment is still uncertain. In an investigation of 5633 patients with Kawasaki disease in the United States, methylprednisolone was used as the second line therapy in 196 patients (27.1%) among the 722 patients unresponsive to initial IVIG[20]. IVIG was the second line drug of choice in 466 patients (64.5%) in this investigation. A nationwide survey in Japan showed that steroids were used exclusively in 2.0% of hospitals and that they were used with additional IVIG in 5.1% of hospitals as the second line therapy for patients unresponsive to initial IVIG[21]. Additional IVIG exclusive administration was the second line treatment of choice in 464 hospitals (44.1%) and a combination of additional IVIG and another drug was selected in another 26% of hospitals in this survey. Therefore, the most common second line treatment is additional IVIG administration currently.

Despite initial IVIG treatment, 6.8%-38.3% of patients are unresponsive to it[22-36] and are at a higher risk for coronary artery lesions[30-33,37]. A study based on the United States national database showed that the resistance rate to initial IVIG therapy was 16.3% (hospital range 8.0%-26.8%)[36]. Authors suggested that highly variable rates among pediatric hospitals are possibly associated with variable diagnostic and treatment patterns at individual hospitals[36]. The rate of resistance to second additional IVIG only treatment was 22.2%-48.6%[18,22,24-26,38], and was not lower than that to initial IVIG treatment. Therefore, a consideration of another therapeutic option in patients unresponsive to the initial IVIG treatment is reasonable, and corticosteroids have been considered as an alternative treatment. Several reports of the use of corticosteroids as a treatment in Kawasaki disease patients unresponsive to initial IVIG treatment are presented in Table 1. In these studies, 164-411 patients with Kawasaki disease were observed, and the rate of unresponsiveness to initial IVIG was 13.4%-18.0%. The definition of unresponsiveness is varied by institute. Persistent fever was used commonly as the definition, but the cut-off level of body temperature, the duration of observation for recrudescent fever, and whether or not the CRP level was used were different for each institute. The duration of observation for recrudescent fever is 36 h according to the definition of the AHA[13], and 24 h was suggested in the recent Japanese guideline[39]. Intravenous methylprednisolone pulse therapy for 3 d was applied in all studies[22-26,40]. The dose was 30 mg/kg per day in most of studies[22-24,26,40], except in one[25]. Oral administration of prednisolone was followed after pulse therapy in 3 studies[22,24,26]. In these studies[22-25,40], a comparative analysis between corticosteroid therapy and additional IVIG treatment was performed and showed no significant difference with respect to the occurrence of coronary artery aneurysms. The frequencies of adverse effects of corticosteroids seemed to be relatively higher in reports by Miura *et al*[26,40]. They defined hypothermia as < 35.0 ℃; bradycardia as a heart rate less than the second percentile of the normal standard; hypertension as a systolic/diastolic blood pressure > 95th percentile of normal standard; hyperglycemia as a fasting blood glucose > 6.99 mmol/L; and hyponatremia as a serum Na+ level < 135 mmol/L[26]. Although any serious adverse effects of corticosteroids inducing irreversible organ damage have not been reported in these studies[22-26,40], a close monitoring of vital signs, blood glucose level, and serum electrolytes level and supportive administration of medications – heparin infusion (15-20 units/kg per hour) and H2 blocker are needed in Kawasaki disease patients receiving corticosteroids. Meanwhile, a high incidence of adrenal suppression which had resolved within 6 mo was reported in patients treated with corticosteroids[41]. In the view of the reduction of fever, corticosteroids seem to be more effective than IVIG[23,25,42]. However, Furukawa *et al*[22] warned of a tendency for recrudescent fever in patients unresponsive to corticosteroids, which could potentially delay the therapeutic decision-making process. Although Miura *et al*[26] suggested increasing the dose of oral prednisolone following third line pulse therapy for the patients with recrudescent fever, whether this strategy could be applied to second line therapy is currently unclear. In addition, the usefulness of corticosteroids in the view of their medical cost is controversial[23-25], and this issue may be dependent on the therapeutic strategy of an institute and on the health system of a society.

There has been no confirmative evidence of a better usefulness of corticosteroids as the second line treatment compared to additional IVIG. The combination of corticosteroids and additional IVIG as the second line therapy needs further study to confirm its efficacy, in spite of small group study[43] supporting it. By the way, this combination has been tried more frequently as the first line treatment instead.

**THE USE OF CORTICOSTEROIDS IN COMBINATION WITH IVIG AS THE ROUTINE FIRST LINE TREATMENT**

By about the year 2000, the combination of corticosteroids and IVIG as the first line therapy was reported shortening the duration of fever and/or reducing the severity of systemic inflammation[44-46]. Okada *et al*[46] reported that the levels of cytokines were lower, the duration of fever was shorter, and the C-reactive protein level decreased more quickly in the patient group who underwent the combination treatment than in the patient group who underwent IVIG treatment only. This result implicates a more rapid reduction of inflammatory reactions in the combination treatment. Wooditch *et al*[47] reported that the inclusion of corticosteroids in aspirin-containing regimens with or without IVIG for the first line treatment of Kawasaki disease reduces the incidence of coronary aneurysms in their meta-analysis. In addition, Inoue *et al*[48] reported that the combination of corticosteroids and IVIG as the first line therapy improved the clinical course and coronary artery outcome in their multicenter prospective study with 178 patients. However, the result of a multicenter randomized double-blind placebo-controlled study by Newburger *et al*[49], in which a single dose of methylprednisolone (30 mg/kg) was administrated did not agree with the result by Inoue *et al*[48] The result of another study of 216 patients in which dexamethasone (0.3 mg/kg per day for 3 d) was combined with IVIG showed no significant difference of coronary outcomes between groups[50]. Therefore, it is less likely that the administration of corticosteroids in combination with IVIG as the routine first line therapy in all Kawasaki disease patients reduces coronary artery lesions. However, further studies to determine the most appropriate regimen of corticosteroids should be needed, because the duration of the administration of corticosteroids (prednisolone was selected) including the period of tapering seems to be longer in studies which reported the efficacy of the combination therapy[45,46,48].

**THE USE OF CORTICOSTEROIDS IN COMBINATION WITH IVIG AS THE FIRST LINE TREATMENT IN SELECTED PATIENTS**

Another strategy of a use of corticosteroids in Kawasaki disease patients is their administration in combination with IVIG in selected patients who are expected to be unresponsive to initial IVIG treatment. Three risk scoring systems for the selection of patients were proposed in Japan (Table 2)[51-53]. The cut-off level of the sum of points in the Kobayashi scoring was changed from ≥ 4 points[51] to ≥ 5 points[39,54,55]. The sensitivity and the specificity for predicting initial IVIG unresponsiveness were 86% and 68% in the Kobayashi scoring model, 78% and 76% in the Egami scoring model, and 77% and 86% in the Sano scoring model, respectively, according to the reports by their respective creators[51-53]. There were following reports showing the efficacy of these three scoring systems[54-57]. The other predictive scoring systems have had no subsequent studies to show their usefulness, or are based on a small number of subjects[31,58-60]. Kobayashi *et al*[51] suggested four different points of their study from the study by Newburger *et al*[49]: the time to start a treatment was 2 d earlier in their study, a the longer duration of the administration of corticosteroids, the selection of patients with a high risk of unresponsiveness to initial IVIG treatment, and the ethnic homogeneity of their subjects[54]. The selection criteria of patients at a high risk have been the most hot issue until recently. The efficacy of the Japanese scoring systems has been tested in other institutes. However, satisfactory results have not been achieved, and an especially low sensitivity has been reported[43,60-63]. The sensitivity and the specificity of the Kobayashi scoring system were 33%-60% and 35%-87%[43,60-63], those of the Egami scoring system were 21.4%-57% and 77%-86.6%[60-62], and those of the Sano scoring system were 40%-60% and 85%-90%[61,62], respectively. These results suggest refinement of the Japanese scoring systems is needed before they can be used effectively. In addition, one recent study whose subjects were patients with incomplete Kawasaki disease, showed that the proportion of patients identified as being at high-risk for IVIG resistance using three Japanese scoring systems were not significantly different between the IVIG resistance group and the IVIG responsive group[64].

Many clinical/laboratory variables have been reported as the predictors of the unresponsiveness to initial IVIG treatment (Table 3)[31-34,37,51-53,58-62,65-73]. The diversity of predictors might be one reason of the low sensitivity of the proposed risk scoring systems. The biomarkers and the genetic variants also have been investigated as the predictors. However, there has been no report in which any aggressive therapy prevented coronary artery lesions in patients at high risk of unresponsiveness predicted by biomarkers and genetic variants. For more information about studies of biomarkers and genetic variants, two recent reviews are informative[74,75].

More-aggressive initial treatment for patients at a high risk of IVIG unresponsiveness after risk stratification using a predictive model has been recommended in the recently updated guidelines for the medical treatment of acute Kawasaki disease in Japan[39]. Future investigations to determine the best predictive model to use are necessary.

**CONCLUSION**

It is uncertain that the corticosteroids as the second line treatment are better than the additional treatment of IVIG in Kawasaki disease patients unresponsive to initial IVIG. It is also uncertain that the combination of corticosteroids and IVIG is better than the initial IVIG only treatment as the routine first line therapy during the acute phase. The therapeutic strategy that an aggressive treatment including the combination of corticosteroids and IVIG is needed in patients at high risk of unresponsiveness to initial IVIG treatment, is properly reasonable. Future investigations to determine the best predictive model for the unresponsiveness are necessary.

**REFERENCES**

1 **Kawasaki T**. [Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children]. *Arerugi* 1967; **16**: 178-222 [PMID: 6062087]

2 **Lehmann C**, Klar R, Lindner J, Lindner P, Wolf H, Gerling S. Kawasaki disease lacks association with human coronavirus NL63 and human bocavirus. *Pediatr Infect Dis J* 2009; **28**: 553-554 [PMID: 19504744]

3 **Kim JH**, Yu JJ, Lee J, Kim MN, Ko HK, Choi HS, Kim YH, Ko JK. Detection rate and clinical impact of respiratory viruses in children with Kawasaki disease. *Korean J Pediatr* 2012; **55**: 470-473 [PMID: 23300502 DOI: 10.3345/kjp.2012.55.12.470]

4 **Rowley AH**, Baker SC, Shulman ST, Rand KH, Tretiakova MS, Perlman EJ, Garcia FL, Tajuddin NF, Fox LM, Huang JH, Ralphe JC, Takahashi K, Flatow J, Lin S, Kalelkar MB, Soriano B, Orenstein JM. Ultrastructural, immunofluorescence, and RNA evidence support the hypothesis of a "new" virus associated with Kawasaki disease. *J Infect Dis* 2011; **203**: 1021-1030 [PMID: 21402552 DOI: 10.1093/infdis/jiq136]

5 **Rodó X**, Curcoll R, Robinson M, Ballester J, Burns JC, Cayan DR, Lipkin WI, Williams BL, Couto-Rodriguez M, Nakamura Y, Uehara R, Tanimoto H, Morguí JA. Tropospheric winds from northeastern China carry the etiologic agent of Kawasaki disease from its source to Japan. *Proc Natl Acad Sci USA* 2014; **111**: 7952-7957 [PMID: 24843117 DOI: 10.1073/pnas.1400380111]

6 **Kim GB**, Park S, Kwon BS, Han JW, Park YW, Hong YM. Evaluation of the Temporal Association between Kawasaki Disease and Viral Infections in South Korea. *Korean Circ J* 2014; **44**: 250-254 [PMID: 25089137 DOI: 10.4070/kcj.2014.44.4.250]

7 **Chang LY**, Lu CY, Shao PL, Lee PI, Lin MT, Fan TY, Cheng AL, Lee WL, Hu JJ, Yeh SJ, Chang CC, Chiang BL, Wu MH, Huang LM. Viral infections associated with Kawasaki disease. *J Formos Med Assoc* 2014; **113**: 148-154 [PMID: 24495555 DOI: 10.1016/j.jfma.2013.12.008]

8 **Xing Y**, Wang H, Liu X, Yu X, Chen R, Wang C, Yu X, Sun L. Meta-analysis of the relationship between single nucleotide polymorphism rs72689236 of caspase-3 and Kawasaki disease. *Mol Biol Rep* 2014; **41**: 6377-6381 [PMID: 24990693 DOI: 10.1007/s11033-014-3517-7]

9 **Chatzikyriakidou A**, Aidinidou L, Giannopoulos A, Papadopoulou-Legbelou K, Kalinderi K, Fidani L. Absence of association of FCGR2A gene polymorphism rs1801274 with Kawasaki disease in Greek patients. *Cardiol Young* 2015; **25**: 681-683 [PMID: 24775607 DOI: 10.1017/S1047951114000626]

10 **Lou J**, Zhong R, Shen N, Lu XZ, Ke JT, Duan JY, Qi YQ, Wang YJ, Zhang Q, Wang W, Gong FQ, Miao XP. Systematic confirmation study of GWAS-identified genetic variants for Kawasaki disease in a Chinese population. *Sci Rep* 2015; **5**: 8194 [PMID: 25645453 DOI: 10.1038/srep08194]

11 **Chang CJ**, Kuo HC, Chang JS, Lee JK, Tsai FJ, Khor CC, Chang LC, Chen SP, Ko TM, Liu YM, Chen YJ, Hong YM, Jang GY, Hibberd ML, Kuijpers T, Burgner D, Levin M, Burns JC, Davila S, Chen YT, Chen CH, Wu JY, Lee YC. Replication and meta-analysis of GWAS identified susceptibility loci in Kawasaki disease confirm the importance of B lymphoid tyrosine kinase (BLK) in disease susceptibility. *PLoS One* 2013; **8**: e72037 [PMID: 24023612 DOI: 10.1371/journal.pone.0072037]

12 **Yoon KL**. Update of genetic susceptibility in patients with Kawasaki disease. *Korean J Pediatr* 2015; **58**: 84-88 [PMID: 25861330 DOI: 10.3345/kjp.2015.58.3.84]

13 **Newburger JW**, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, Shulman ST, Bolger AF, Ferrieri P, Baltimore RS, Wilson WR, Baddour LM, Levison ME, Pallasch TJ, Falace DA, Taubert KA. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. *Pediatrics* 2004; **114**: 1708-1733 [PMID: 15574639]

14 **Kato H**, Koike S, Yokoyama T. Kawasaki disease: effect of treatment on coronary artery involvement. *Pediatrics* 1979; **63**: 175-179 [PMID: 440805]

15 **Kijima Y**, Kamiya T, Suzuki A, Hirose O, Manabe H. A trial procedure to prevent aneurysm formation of the coronary arteries by steroid pulse therapy in Kawasaki disease. *Jpn Circ J* 1982; **46**: 1239-1242 [PMID: 7131714]

16 **Furusho K**, Kamiya T, Nakano H, Kiyosawa N, Shinomiya K, Hayashidera T, Tamura T, Hirose O, Manabe Y, Yokoyama T. High-dose intravenous gammaglobulin for Kawasaki disease. *Lancet* 1984; **2**: 1055-1058 [PMID: 6209513]

17 **Wright DA**, Newburger JW, Baker A, Sundel RP. Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids. *J Pediatr* 1996; **128**: 146-149 [PMID: 8551407]

18 **Wallace CA**, French JW, Kahn SJ, Sherry DD. Initial intravenous gammaglobulin treatment failure in Kawasaki disease. *Pediatrics* 2000; **105**: E78 [PMID: 10835091]

19 **Dale RC**, Saleem MA, Daw S, Dillon MJ. Treatment of severe complicated Kawasaki disease with oral prednisolone and aspirin. *J Pediatr* 2000; **137**: 723-726 [PMID: 11060542]

20 **Ghelani SJ**, Pastor W, Parikh K. Demographic and treatment variability of refractory kawasaki disease: a multicenter analysis from 2005 to 2009. *Hosp Pediatr* 2012; **2**: 71-76 [PMID: 24510952 DOI: 10.1542/hpeds.2011-00112]

21 **Uehara R**, Yashiro M, Oki I, Nakamura Y, Yanagawa H. Re-treatment regimens for acute stage of Kawasaki disease patients who failed to respond to initial intravenous immunoglobulin therapy: analysis from the 17th nationwide survey. *Pediatr Int* 2007; **49**: 427-430 [PMID: 17587262]

22 **Furukawa T**, Kishiro M, Akimoto K, Nagata S, Shimizu T, Yamashiro Y. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease. *Arch Dis Child* 2008; **93**: 142-146 [PMID: 17962370]

23 **Ogata S**, Bando Y, Kimura S, Ando H, Nakahata Y, Ogihara Y, Kaneko T, Minoura K, Kaida M, Yokota Y, Furukawa S, Ishii M. The strategy of immune globulin resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. *J Cardiol* 2009; **53**: 15-19 [PMID: 19167633 DOI: 10.1016/j.jjcc.2008.08.002]

24 **Teraguchi M**, Ogino H, Yoshimura K, Taniuchi S, Kino M, Okazaki H, Kaneko K. Steroid pulse therapy for children with intravenous immunoglobulin therapy-resistant Kawasaki disease: a prospective study. *Pediatr Cardiol* 2013; **34**: 959-963 [PMID: 23184018 DOI: 10.1007/s00246-012-0589-9]

25 **Hashino K**, Ishii M, Iemura M, Akagi T, Kato H. Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. *Pediatr Int* 2001; **43**: 211-217 [PMID: 11380911]

26 **Miura M**, Tamame T, Naganuma T, Chinen S, Matsuoka M, Ohki H. Steroid pulse therapy for Kawasaki disease unresponsive to additional immunoglobulin therapy. *Paediatr Child Health* 2011; **16**: 479-484 [PMID: 23024586]

27 **Durongpisitkul K**, Soongswang J, Laohaprasitiporn D, Nana A, Prachuabmoh C, Kangkagate C. Immunoglobulin failure and retreatment in Kawasaki disease. *Pediatr Cardiol* 2003; **24**: 145-148 [PMID: 12457253]

28 **Han RK**, Silverman ED, Newman A, McCrindle BW. Management and outcome of persistent or recurrent fever after initial intravenous gamma globulin therapy in acute Kawasaki disease. *Arch Pediatr Adolesc Med* 2000; **154**: 694-699 [PMID: 10891021]

29 **Kashef S**, Safari M, Amin R. Initial intravenous gamma-globulin treatment failure in Iranian children with Kawasaki disease. *Kaohsiung J Med Sci* 2005; **21**: 401-404 [PMID: 16248123]

30 **Burns JC**, Capparelli EV, Brown JA, Newburger JW, Glode MP. Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US/Canadian Kawasaki Syndrome Study Group. *Pediatr Infect Dis J* 1998; **17**: 1144-1148 [PMID: 9877364]

31 **Tremoulet AH**, Best BM, Song S, Wang S, Corinaldesi E, Eichenfield JR, Martin DD, Newburger JW, Burns JC. Resistance to intravenous immunoglobulin in children with Kawasaki disease. *J Pediatr* 2008; **153**: 117-121 [PMID: 18571548 DOI: 10.1016/j.jpeds.2007.12.021]

32 **Wei M**, Huang M, Chen S, Huang G, Huang M, Qiu D, Guo Z, Jiang J, Zhou X, Yu Q, Guo Y, Fu L, Gao W, Li F. A Multicenter Study of Intravenous Immunoglobulin Non-response in Kawasaki Disease. *Pediatr Cardiol* 2015; **36**: 1166-1172 [PMID: 25812827]

33 **Uehara R**, Belay ED, Maddox RA, Holman RC, Nakamura Y, Yashiro M, Oki I, Ogino H, Schonberger LB, Yanagawa H. Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan. *Pediatr Infect Dis J* 2008; **27**: 155-160 [PMID: 18174868 DOI: 10.1097/INF.0b013e31815922b5]

34 **Ashouri N**, Takahashi M, Dorey F, Mason W. Risk factors for nonresponse to therapy in Kawasaki disease. *J Pediatr* 2008; **153**: 365-368 [PMID: 18534243 DOI: 10.1016/j.jpeds.2008.03.014]

35 **Nakada T**. Effects of anti-inflammatory drugs on intravenous immunoglobulin therapy in the acute phase of Kawasaki disease. *Pediatr Cardiol* 2015; **36**: 335-339 [PMID: 25158631 DOI: 10.1007/s00246-014-1010-7]

36 **Moffett BS**, Syblik D, Denfield S, Altman C, Tejtel-Sexson K. Epidemiology of immunoglobulin resistant kawasaki disease: results from a large, national database. *Pediatr Cardiol* 2015; **36**: 374-378 [PMID: 25179461 DOI: 10.1007/s00246-014-1016-1]

37 **Sittiwangkul R**, Pongprot Y, Silvilairat S, Phornphutkul C. Management and outcome of intravenous gammaglobulin-resistant Kawasaki disease. *Singapore Med J* 2006; **47**: 780-784 [PMID: 16924360]

38 **Suzuki H**, Terai M, Hamada H, Honda T, Suenaga T, Takeuchi T, Yoshikawa N, Shibuta S, Miyawaki M, Oishi K, Yamaga H, Aoyagi N, Iwahashi S, Miyashita R, Onouchi Y, Sasago K, Suzuki Y, Hata A. Cyclosporin A treatment for Kawasaki disease refractory to initial and additional intravenous immunoglobulin. *Pediatr Infect Dis J* 2011; **30**: 871-876 [PMID: 21587094 DOI: 10.1097/INF.0b013e318220c3cf]

39 **Research Committee of the Japanese Society of Pediatric Cardiology**, [Cardiac Surgery Committee for Development of Guidelines for Medical Treatment of Acute Kawasaki Disease](http://www.ncbi.nlm.nih.gov/pubmed/?term=Cardiac%20Surgery%20Committee%20for%20Development%20of%20Guidelines%20for%20Medical%20Treatment%20of%20Acute%20Kawasaki%20Disease%5BCorporate%20Author%5D). Guidelines for medical treatment of acute Kawasaki disease: report of the Research Committee of the Japanese Society of Pediatric Cardiology and Cardiac Surgery (2012 revised version). *Pediatr Int* 2014; **56**: 135-158 [PMID: 24730626 DOI: 10.1111/ped.12317]

40 **Miura M**, Ohki H, Yoshiba S, Ueda H, Sugaya A, Satoh M, Yamagishi H. Adverse effects of methylprednisolone pulse therapy in refractory Kawasaki disease. *Arch Dis Child* 2005; **90**: 1096-1097 [PMID: 16177169]

41 **Goto M**, Miyagawa N, Kikunaga K, Miura M, Hasegawa Y. High incidence of adrenal suppression in children with Kawasaki disease treated with intravenous immunoglobulin plus prednisolone. *Endocr J* 2015; **62**: 145-151 [PMID: 25342092 DOI: 10.1507/endocrj.EJ14-0385]

42 **Yang X**, Liu G, Huang Y, Chen S, Du J, Jin H. A meta-analysis of re-treatment for intravenous immunoglobulin-resistant Kawasaki disease. *Cardiol Young* 2015; **25**: 1182-1190 [PMID: 25597708]

43 **Jibiki T**, Kato I, Shiohama T, Abe K, Anzai S, Takeda N, Yamaguchi K, Kanazawa M, Kurosaki T. Intravenous immune globulin plus corticosteroids in refractory Kawasaki disease. *Pediatr Int* 2011; **53**: 729-735 [PMID: 21342358 DOI: 10.1111/j.1442-200X.2011.03338.x]

44 **Sundel RP**, Baker AL, Fulton DR, Newburger JW. Corticosteroids in the initial treatment of Kawasaki disease: report of a randomized trial. *J Pediatr* 2003; **142**: 611-616 [PMID: 12838187]

45 **Shinohara M**, Sone K, Tomomasa T, Morikawa A. Corticosteroids in the treatment of the acute phase of Kawasaki disease. *J Pediatr* 1999; **135**: 465-469 [PMID: 10518080]

46 **Okada Y**, Shinohara M, Kobayashi T, Inoue Y, Tomomasa T, Kobayashi T, Morikawa A. Effect of corticosteroids in addition to intravenous gamma globulin therapy on serum cytokine levels in the acute phase of Kawasaki disease in children. *J Pediatr* 2003; **143**: 363-367 [PMID: 14517521]

47 **Wooditch AC**, Aronoff SC. Effect of initial corticosteroid therapy on coronary artery aneurysm formation in Kawasaki disease: a meta-analysis of 862 children. *Pediatrics* 2005; **116**: 989-995 [PMID: 16199713]

48 **Inoue Y**, Okada Y, Shinohara M, Kobayashi T, Kobayashi T, Tomomasa T, Takeuchi K, Morikawa A. A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: clinical course and coronary artery outcome. *J Pediatr* 2006; **149**: 336-341 [PMID: 16939743]

49 **Newburger JW**, Sleeper LA, McCrindle BW, Minich LL, Gersony W, Vetter VL, Atz AM, Li JS, Takahashi M, Baker AL, Colan SD, Mitchell PD, Klein GL, Sundel RP. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. *N Engl J Med* 2007; **356**: 663-675 [PMID: 17301297]

50 **Lim YJ**, Jung JW. Clinical outcomes of initial dexamethasone treatment combined with a single high dose of intravenous immunoglobulin for primary treatment of Kawasaki disease. *Yonsei Med J* 2014; **55**: 1260-1266 [PMID: 25048483 DOI: 10.3349/ymj.2014.55.5.1260]

51 **Kobayashi T**, Inoue Y, Takeuchi K, Okada Y, Tamura K, Tomomasa T, Kobayashi T, Morikawa A. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. *Circulation* 2006; **113**: 2606-2612 [PMID: 16735679]

52 **Egami K**, Muta H, Ishii M, Suda K, Sugahara Y, Iemura M, Matsuishi T. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. *J Pediatr* 2006; **149**: 237-240 [PMID: 16887442]

53 **Sano T**, Kurotobi S, Matsuzaki K, Yamamoto T, Maki I, Miki K, Kogaki S, Hara J. Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment. *Eur J Pediatr* 2007; **166**: 131-137 [PMID: 16896641]

54 **Kobayashi T**, Saji T, Otani T, Takeuchi K, Nakamura T, Arakawa H, Kato T, Hara T, Hamaoka K, Ogawa S, Miura M, Nomura Y, Fuse S, Ichida F, Seki M, Fukazawa R, Ogawa C, Furuno K, Tokunaga H, Takatsuki S, Hara S, Morikawa A. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. *Lancet* 2012; **379**: 1613-1620 [PMID: 22405251 DOI: 10.1016/S0140-6736(11)61930-2]

55 **Kobayashi T**, Inoue Y, Otani T, Morikawa A, Kobayashi T, Takeuchi K, Saji T, Sonobe T, Ogawa S, Miura M, Arakawa H. Risk stratification in the decision to include prednisolone with intravenous immunoglobulin in primary therapy of Kawasaki disease. *Pediatr Infect Dis J* 2009; **28**: 498-502 [PMID: 19504733]

56 **Ogata S**, Ogihara Y, Honda T, Kon S, Akiyama K, Ishii M. Corticosteroid pulse combination therapy for refractory Kawasaki disease: a randomized trial. *Pediatrics* 2012; **129**: e17-e23 [PMID: 22144699 DOI: 10.1542/peds.2011-0148]

57 **Okada K**, Hara J, Maki I, Miki K, Matsuzaki K, Matsuoka T, Yamamoto T, Nishigaki T, Kurotobi S, Sano T. Pulse methylprednisolone with gammaglobulin as an initial treatment for acute Kawasaki disease. *Eur J Pediatr* 2009; **168**: 181-185 [PMID: 18446365 DOI: 10.1007/s00431-008-0727-9]

58 **Seki M**, Kobayashi T, Kobayashi T, Morikawa A, Otani T, Takeuchi K, Ayusawa M, Tsuchiya K, Yasuda K, Suzuki T, Shimoyama S, Ikeda K, Ishii Y, Arakawa H. External validation of a risk score to predict intravenous immunoglobulin resistance in patients with kawasaki disease. *Pediatr Infect Dis J* 2011; **30**: 145-147 [PMID: 20802375 DOI: 10.1097/INF.0b013e3181f386db]

59 **Fukunishi M**, Kikkawa M, Hamana K, Onodera T, Matsuzaki K, Matsumoto Y, Hara J. Prediction of non-responsiveness to intravenous high-dose gamma-globulin therapy in patients with Kawasaki disease at onset. *J Pediatr* 2000; **137**: 172-176 [PMID: 10931407]

60 **Fu PP**, Du ZD, Pan YS. Novel predictors of intravenous immunoglobulin resistance in Chinese children with Kawasaki disease. *Pediatr Infect Dis J* 2013; **32**: e319-e323 [PMID: 23446442 DOI: 10.1097/INF.0b013e31828e887f]

61 **Sleeper LA**, Minich LL, McCrindle BM, Li JS, Mason W, Colan SD, Atz AM, Printz BF, Baker A, Vetter VL, Newburger JW. Evaluation of Kawasaki disease risk-scoring systems for intravenous immunoglobulin resistance. *J Pediatr* 2011; **158**: 831-835.e3 [PMID: 21168857 DOI: 10.1016/j.jpeds.2010.10.031]

62 **Park HM**, Lee DW, Hyun MC, Lee SB. Predictors of nonresponse to intravenous immunoglobulin therapy in Kawasaki disease. *Korean J Pediatr* 2013; **56**: 75-79 [PMID: 23482814 DOI: 10.3345/kjp.2013.56.2.75]

63 **Davies S**, Sutton N, Blackstock S, Gormley S, Hoggart CJ, Levin M, Herberg JA. Predicting IVIG resistance in UK Kawasaki disease. *Arch Dis Child* 2015; **100**: 366-368 [PMID: 25670405 DOI: 10.1136/archdischild-2014-307397]

64 **Kanamitsu K**, Kakimoto H, Shimada A, Nakata Y, Ochi H, Watanabe H, Iwasaki Y, Tokorodani C, Kanazawa A, Maruyama H, Miyazawa M, Nishiuchi R, Kikkawa K. Verification of risk scores to predict intravenous immunoglobulin resistance in incomplete Kawasaki disease. *Pediatr Int* 2015; Epub ahead of print [PMID: 26190225 DOI: 10.1111/ped.12755]

65 **Lin MC**, Fu YC, Jan SL, Lai MS. Comparative effectiveness of intravenous immunoglobulin for children with Kawasaki disease: a nationwide cohort study. *PLoS One* 2013; **8**: e63399 [PMID: 23650564 DOI: 10.1371/journal.pone.0063399]

66 **Tsai MH**, Huang YC, Yen MH, Li CC, Chiu CH, Lin PY, Lin TY, Chang LY. Clinical responses of patients with Kawasaki disease to different brands of intravenous immunoglobulin. *J Pediatr* 2006; **148**: 38-43 [PMID: 16423595]

67 **Kuo HC**, Liang CD, Wang CL, Yu HR, Hwang KP, Yang KD. Serum albumin level predicts initial intravenous immunoglobulin treatment failure in Kawasaki disease. *Acta Paediatr* 2010; **99**: 1578-1583 [PMID: 20491705 DOI: 10.1111/j.1651-2227.2010.01875.x]

68 **Kuo HC**, Yang KD, Liang CD, Bong CN, Yu HR, Wang L, Wang CL. The relationship of eosinophilia to intravenous immunoglobulin treatment failure in Kawasaki disease. *Pediatr Allergy Immunol* 2007; **18**: 354-359 [PMID: 17584314]

69 **Hwang JY**, Lee KY, Rhim JW, Youn YS, Oh JH, Han JW, Lee JS, Burgner D. Assessment of intravenous immunoglobulin non-responders in Kawasaki disease. *Arch Dis Child* 2011; **96**: 1088-1090 [PMID: 20551193 DOI: 10.1136/adc.2010.184101]

70 **Chen CJ**, Huang FC, Tiao MM, Huang YH, Lin LY, Yu HR, Yang KD, Huang YC, Chen CC, Chang WC, Kuo HC. Sonographic gallbladder abnormality is associated with intravenous immunoglobulin resistance in Kawasaki disease. *ScientificWorldJournal* 2012; **2012**: 485758 [PMID: 22792043 DOI: 10.1100/2012/485758]

71 **Muta H**, Ishii M, Egami K, Furui J, Sugahara Y, Akagi T, Nakamura Y, Yanagawa H, Matsuishi T. Early intravenous gamma-globulin treatment for Kawasaki disease: the nationwide surveys in Japan. *J Pediatr* 2004; **144**: 496-499 [PMID: 15069399]

72 **Cha S**, Yoon M, Ahn Y, Han M, Yoon KL. Risk factors for failure of initial intravenous immunoglobulin treatment in Kawasaki disease. *J Korean Med Sci* 2008; **23**: 718-722 [PMID: 18756064 DOI: 10.3346/jkms.2008.23.4.718]

73 **Tajima M**, Shiozawa Y, Kagawa J. Early Appearance of Principal Symptoms of Kawasaki Disease is a Risk Factor for Intravenous Immunoglobulin Resistance. *Pediatr Cardiol* 2015; **36**: 1159-1165 [PMID: 25753685]

74 **Kuo HC**, Hsu YW, Wu MS, Chien SC, Liu SF, Chang WC. Intravenous immunoglobulin, pharmacogenomics, and Kawasaki disease. *J Microbiol Immunol Infect* 2014; Epub ahead of print [PMID: 25556045 DOI: 10.1016/j.jmii.2014.11.001]

75 **Wakiguchi H**, Hasegawa S, Suzuki Y, Kudo K, Ichiyama T. Relationship between T-cell HLA-DR expression and intravenous immunoglobulin treatment response in Kawasaki disease. *Pediatr Res* 2015; **77**: 536-540 [PMID: 25580740 DOI: 10.1038/pr.2015.12]

**P-Reviewer:** Gonzalez-Granado LI, Toubi E **S-Editor:** Ji FF **L-Editor: E-Editor:**

**Table 1 Re-treatment with corticosteroids or additional intravenous immunoglobulin in Kawasaki disease patients unresponsive to initial intravenous immunoglobulin**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **No. of patients****with KD** | **Definition of** **unresponsiveness:** **BT, obs period, other** | **No. of patients****unresponsive to initial IVIG** | **Stage****of CS Tx** | **Regimen** | **No. of patients****re-Tx** | **Tx day after fever onset1** | **No. of patients****with response** | **No. of patients****with CAA** | **No. of patients with adverse****effects** |
| [22] | 411 | 36 h after IVIG | 63 | 2nd line | IVMP 30 mg/kg per day, 3 dFollowed Pd | 44 | 7 (6-8) | 34 | 5 | Hypertension 5, hypothermia 3, bradycardia 3, transient paralysis 1 |
|  |  |  |  |  | IVIG 1-2 g/kg | 19 | 8 (5-11) | 12 | 2 |  |
| [40] | NA | ≥ 37.5 ℃, 48 h after IVIG | 22 | 2nd line | IVMP 30 mg/kg per day, 3 d | 11 | NA | NA | 2 | Hypertension 10, hypothermia 1, bradycardia 9, hyperglycemia 6, aPTT↓ 3 |
|  |  |  |  |  | IVIG 2 g/kg | 11 | NA | NA | 3 |  |
| [23] | 164 | ≥ 37.5 ℃, 36-48 h after IVIGCRP↓ ≤ 50% | 27 | 2nd line | IVMP 30 mg/kg per day, 3 d | 13 | 7 ± 1.3 | NA | 0 | Bradycardia 2 |
|  |  |  |  |  | IVIG 2g/kg | 14 | 8 ± 2.4 | NA | 3 |  |
| [24] | 237 | ≥ 38 ℃, 36 h after IVIG37.5 ℃-38 ℃ and CRP↓ ≤ 50% | 41 | 2nd line | IVMP 30 mg/kg per day, 3 dFollowed Pd | 14 | 7 (7-9) | 7 | 5 | Gastrointestinal bleeding 1 |
|  |  |  |  |  | IVIG 2 g/kg | 27 | 8 (5-14) | 21 | 7 |  |
| [25] | 262 | ≥ 37.5 ℃, 48 h after IVIGCRP↓ ≤ 50% | 35 | 3rd line | IVMP 20 mg/kg per day, 3 d | 9 | NA | NA | 7 | NA |
|  |  |  |  |  | IVIG 1 g/kg | 8 | NA | NA | 5 |  |
| [26] | 412 | 48 h after IVIG | 74 | 3rd line | IVMP 30 mg/kg per day, 3 dFollowed Pd | 21 | 8 (IQR 8-9) | 21 | 2 | Hypertension 17, hypothermia 3, bradycardia 17, hyperglycemia 7, serum Na↓ 4 |

1Median (range), median (IQR), or mean ± SD. IVIG: Intravenous immunoglobulin; KD: Kawasaki disease; BT: Body temperature; obs: Observation; Tx: Treatment; CS: Corticosteroids; CAA: Coronary artery aneurysm; NA: Not available; IVMP: Intravenous methylprednisolone pulse; Pd: Oral prednisolone; IQR: Interquartile range.

**Table 2 Risk scoring systems for the selection of patients expected to have unresponsiveness to initial intravenous immunoglobulin treatment**

|  |  |  |
| --- | --- | --- |
|  | **Cut-off** | **Points** |
| **Kobayashi score (≥ 4-5 points)[51,54,55]** |
| Age | ≤ 12 mo | 1 |
| Days of illness at initial treatment  | ≤ 4 | 2 |
| Platelet count | ≤ 300×103/mm3 | 1 |
| Neutrophil | ≥ 80% | 2 |
| CRP | ≥ 10 mg/dL | 1 |
| AST | ≥ 100 IU/L | 2 |
| Sodium | ≤ 133 mmol/L | 2 |
| **Egami score (≥ 3 points)[52]** |
| Age | ≤ 6 mo | 1 |
| Days of illness at initial treatment | ≤ 4 | 1 |
| Platelet count | ≤ 300 × 103/mm3 | 1 |
| CRP | ≥ 8 mg/dL | 1 |
| ALT | ≥ 80 IU/L | 2 |
| **Sano score (≥ 2 points)[53]** |
| CRP | ≥ 7 mg/dL | 1 |
| AST | ≥ 200 IU/L | 1 |
| Total bilirubin | ≥ 0.9 mg/dL | 1 |

IVIG: Intravenous immunoglobulin; CRP: C-reactive protein; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase.

**Table 3 Clinical and laboratory variables associated with the unresponsiveness to initial intravenous immunoglobulin treatment**

|  |  |  |
| --- | --- | --- |
|  | **Risk factors** | **Ref.** |
| Age | ≤ 6-12 mo | [51,52,58] |
| Sex | Male | [33,61] |
| Duration of fever | Long duration | [58,69] |
| Days of illness at initial treatment | ≤ 4 | [31,33,51,52,58,60,71] |
| Recurrent Kawasaki disease | Recurrent case | [33] |
| Principal features/symptoms | Early appearancePolymorphous exanthemaLymphadenopathy | [72][60][32] |
| Other physical findings | Changes around anus | [60] |
| Brand of IVIG | β-propiolactone | [65,66] |
| Neutrophil | ≥ 80%, or increased | [51,58,60,69,72] |
| Band form  | ≥ 20%, or increased | [31,34] |
| Hemoglobin | Anemia by age, < 10 g/dL | [31,59] |
| Eosinophil count | High level – good response | [68] |
| Platelet count | ≤ 300 × 103/mm3, or decreased≥ 530 × 103/mm3 | [51,52,58,72][32] |
| ESR | ≥ 75 mm/h, or increased | [32,37] |
| CRP | ≥ 7-10 mg/dL, or increased | [51-53,58-60,69] |
| Albumin | Lower than normal | [34,61,67] |
| ALT | ≥ 80-84 IU/L | [52,62] |
| AST | ≥ 100-200 IU/L, or increased | [51,53,61,72] |
| Total bilirubin | ≥ 0.9 mg/dL, or increased | [53,62,72] |
| γGlutamyl transferase | ≥ 60 IU/L | [31] |
| Lactate dehydrogenase | >590IU/L | [59] |
| Sodium | ≤ 133 mmol/L | [51] |
| Imaging studies | Sonographic GB abnormalities | [70] |

IVIG: Intravenous immunoglobulin; ESR: Erythrocyte sedimentation rate; CRP: C-reactive protein; NT-proBNP: N-terminal fragment of B-type natriuretic peptide; GB: Gall bladder.